docetaxel anhydrous has been researched along with cyclin d1 in 12 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Christen, RD; Gerhold, M; Lin, X; Nehmé, A; Niedner, H; Sellakumar, G; Varadarajan, P; Zhang, Q | 1 |
| Atago, Y; Fukuda, S; Furuta, Y; Higuchi, E; Homma, A; Nagahashi, T; Oridate, N; Suzuki, F | 1 |
| Bologna, M; D'Alessandro, AM; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Vicentini, C | 1 |
| Li, J; Li, XR; Liu, M; Ma, B; Song, X; Wang, JD; Zhang, YJ; Zheng, YQ | 1 |
| Brown, I; Kastl, L; Schofield, AC | 1 |
| Kang, HS; Kim, JH; Ro, J; Yoo, HI; Yoon, S | 1 |
| Cooke, LS; Fisher, RI; Mahadevan, D; Manziello, A; Miller, TP; Morales, C; Persky, DO; Qi, W; Stejskal, A | 1 |
| Lee, JJ; Li, J; Liu, Y; Ma, J; Myers, JN; Wang, LZ; William, WN; Yang, CZ; Yang, X; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, DW | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| Bansal, N; Bertino, JR; DiPaola, RS; Mishra, PJ; Stein, M | 1 |
| Corcos, L; Durand, S; El Khoury, F; Le Jossic-Corcos, C; Simon, B | 1 |
| Liu, L; Ma, C; Tang, H; Xiong, W; Zhao, Y | 1 |
2 trial(s) available for docetaxel anhydrous and cyclin d1
| Article | Year |
|---|---|
Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Taxoids | 2007 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
10 other study(ies) available for docetaxel anhydrous and cyclin d1
| Article | Year |
|---|---|
Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cyclin D1; Docetaxel; Down-Regulation; Drug Interactions; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Tretinoin; Tumor Cells, Cultured | 2001 |
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Docetaxel; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Cyclin D1; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; NM23 Nucleoside Diphosphate Kinases; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Young Adult | 2011 |
miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Topics: Antineoplastic Agents; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cyclin D1; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Reproducibility of Results; Taxoids | 2012 |
Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest.
Topics: Antimitotic Agents; Apoptosis; Cell Line, Tumor; Colchicine; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Paclitaxel; Pyrans; Taxoids; Vinblastine | 2012 |
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, Nuclear; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin D1; Docetaxel; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Spindle Apparatus; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2012 |
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclin D1; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Prognosis; Taxoids | 2013 |
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Docetaxel; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; Male; Metformin; Neoplasm Invasiveness; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Taxoids; Triazoles; Up-Regulation | 2015 |
Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Adhesion Molecules, Neuronal; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dipeptidyl Peptidase 4; Docetaxel; Drug Resistance, Neoplasm; Fetal Proteins; HCT116 Cells; HT29 Cells; Humans; Integrin beta1; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Phenotype; Receptor, EphB2; Taxoids | 2016 |
Efficacy of trastuzumab combined with cisplatin and docetaxel on gastric cardia carcinoma and its influence on HER2 and cyclin D1 expressions.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardia; Cisplatin; Cyclin D1; Docetaxel; Humans; Neoplasm Proteins; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |